Successful use of recombinant FVIIa (Novoseven®) in the management of uncontrolled bleeding after emergency fasciotomy

被引：4
|
作者：
Sipahi, T. [1 ]
Kuybulu, A. [1 ]
机构：
[1] Suleyman Demirel Univ, Fac Med, Dept Pediat, Pediat Hematol Unit, TR-32200 Isparta, Turkey
来源：
HAEMOPHILIA | 2008年 / 14卷 / 05期
关键词：
D O I：
10.1111/j.1365-2516.2008.01801.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1145 / 1146
页数：2
相关论文
共 50 条
  • [21] Recombinant activated factor VII (NovoSeven™), an adjunct to replacement therapy in acute, uncontrolled, life threatening bleeding.
    Ben-Tal, O
    Misgav, M
    Kluger, Y
    Greenberg, R
    Klausner, J
    Pausner, D
    Mayo, A
    BLOOD, 2003, 102 (11) : 132B - 132B
  • [22] Recombinant (r) FVIIa (NovoSeven) for treatment of bleeding episodes in children with hemophilia B complicated by inhibitor antibodies and anaphylaxis to F IX products
    Warrier, I
    Lusher, JM
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS201 - PS201
  • [23] Successful management of bleeding with recombinant factor Vila (NovoSeven®) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins
    Culic, Srdana
    Kuljis, Dubravka
    Armanda, Visnja
    Jankovic, Stipan
    PEDIATRIC BLOOD & CANCER, 2007, 49 (03) : 332 - 335
  • [24] Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies:: results from the NovoSeven® emergency-use programme in patients with severe haemophilia or with acquired inhibitors
    Arkin, S
    Blei, F
    Fetten, J
    Foulke, R
    Gilchrist, GS
    Heisel, MA
    Key, N
    Kisker, CT
    Kitchen, C
    Shafer, FE
    Shah, PC
    Strickland, D
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (03) : 255 - 259
  • [25] Successful emergency management of a bleeding tracheoinnominate fistula
    Donaldson, Lachlan
    Raper, Raymond
    BMJ CASE REPORTS, 2019, 12 (12)
  • [26] Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
    Mariko Ishihara
    Yoshikazu Miyamoto
    Akihiro Taniguchi
    Keiko Kinouchi
    JA Clinical Reports, 1 (1)
  • [27] Use of recombinant factor Vlla (NovoSeven®) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia
    Slappendel, R
    Huvers, FC
    Benraad, B
    Novakova, I
    van Hellemondt, GG
    ANESTHESIOLOGY, 2002, 96 (06) : 1525 - 1527
  • [28] Successful use of recombinant FVIIa in combined factor V and FVIII deficiency with surgical bleeding resistant to substitutive treatment. A case report
    Di Marzio, I.
    Iuliani, O.
    Malizia, R.
    Rolandi, G.
    Sanna, S.
    Castaman, G.
    Dragani, A.
    HAEMOPHILIA, 2011, 17 (01) : 160 - 161
  • [29] Successful use of recombinant activated factor VII (eptacog alfa, Novoseven (R)) in a refractory bleeding during pediatric cardiac surgery: a case report
    Ishihara, Mariko
    Miyamoto, Yoshikazu
    Taniguchi, Akihiro
    Kinouchi, Keiko
    JA CLINICAL REPORTS, 2015, 1
  • [30] Use of Recombinant Factor VII a (NovoSeven) in Patients with Ongoing Life Threatening Bleeding Treated with Fondaparinux
    Schiele, Francois
    Luporsi, Paul
    Meneveau, Nicolas
    Racadot, Evelyne
    Descotes-Genon, Vincent
    Chopard, Romain
    Seronde, Marie-France
    Janin, Sebastien
    CIRCULATION, 2010, 122 (21)
12345